Dizal (Jiangsu) Pharmaceutical (SHA:688192) presented the efficacy results of its DZD8586 drug for B-cell non-Hodgkin lymphoma during a meeting of the American Society of Hematology.
The drug is indicated to hurdle Bruton's tyrosine kinase resistance mutations and is effective against tumors, according to a Tuesday filing with the Shanghai Stock Exchange.
B-cell non-Hodgkin lymphoma targets the body's lymphatic system and is a malignant cancer prone to relapse following treatment, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。